Business
Cogent Biosciences to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference
CAMBRIDGE, Mass., Nov. 5, 2020 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for
About this update from Cogent Biosciences, Inc.
[{"type":"text","content":"CAMBRIDGE, Mass., Nov. 5, 2020 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins, Chief Executive Officer and President, will virtually present a corporate overview at the Piper Sandler 32nd Annual Healthcare Conference taking place December 1-3, 2020. \n\n \n \n \n \n \n \n\n \nA recording of the presentation will be available to view after the conference under the \"Events\" tab on the investor relations section of the Cogent Biosciences website at: https://investors.cogentbio.com/events. \nAbout Cogent Biosciences, Inc.Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, PLX9486, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. Cogent Biosciences is headquartered in Cambridge, MA. Visit our website for more information at www.cogentbio.com. Follow Cogent Biosciences on social media: Twitter and LinkedIn.\nForward Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, pertaining to the company's planned participation at an investor conference, which may include discussion of the company's business and operations, projected cash runways; future product development plans; and upcoming results from clinical trials. The use of words such as, but not limited to, \"anticipate,\" \"believe,\" \"continue,\" \"could,\" \"estimate,\" \"expect,\" \"intend,\" \"may,\" \"might,\" \"plan,\" \"potential,\" \"predict,\" \"project,\" \"should,\" \"target,\" \"will,\" or \"would\" and similar words expressions are intended to identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptio...